Suppr超能文献

MiR-21的预后价值:头颈部鳞状细胞癌(HNSCC)的最新荟萃分析

Prognostic Value of MiR-21: An Updated Meta-Analysis in Head and Neck Squamous Cell Carcinoma (HNSCC).

作者信息

Irimie-Aghiorghiesei Alexandra Iulia, Pop-Bica Cecilia, Pintea Sebastian, Braicu Cornelia, Cojocneanu Roxana, Zimța Alina-Andreea, Gulei Diana, Slabý Ondřej, Berindan-Neagoe Ioana

机构信息

Department of Prosthetic dentistry and Dental materials, Division Dental Propaedeutics, Aesthetic, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania.

Research Center for Functional Genomics and Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania.

出版信息

J Clin Med. 2019 Nov 21;8(12):2041. doi: 10.3390/jcm8122041.

Abstract

Head and neck squamous cell carcinoma (HNSCC) is a group of malignancies with serious impact on patient quality of life due to a reduced rate of response to chemotherapy or radiation therapy. MiR-21 has been identified as one of the most common proto-oncogenes. It is hypothesized that upregulated miR-21 could serve as a potential biomarker for human cancer diagnosis. Considering the target genes identified for miR-21 in HNSCC, this transcript is an important player in several cellular processes that control carcinogenesis. The abnormal expression of miR-21 in this group of pathologies has been assessed in several publications, but given the heterogeneity of the published results, a meta-analysis and proper bioinformatics analysis of expression databases are needed to correctly establish the prognostic potential of this molecule. The present meta-analysis comprises the published survival data on HNSCC patients, reported as HR and 95% CI, in association with the expression levels of miR-21. Our investigation revealed that miR-21 could be used successfully as a prognostic biomarker in HNSCC patients, confirming its oncogenic potential. Specifically, the upregulation of miR-21 in these patients predicts a worse outcome in terms of survival rate.

摘要

头颈部鳞状细胞癌(HNSCC)是一组恶性肿瘤,由于对化疗或放疗的反应率降低,对患者生活质量有严重影响。MiR-21已被确定为最常见的原癌基因之一。据推测,上调的MiR-21可能作为人类癌症诊断的潜在生物标志物。考虑到在HNSCC中确定的MiR-21的靶基因,该转录本在控制致癌作用的几个细胞过程中起着重要作用。在一些出版物中已经评估了MiR-21在这组病理中的异常表达,但鉴于已发表结果的异质性,需要对表达数据库进行荟萃分析和适当的生物信息学分析,以正确确定该分子的预后潜力。本荟萃分析包括已发表的HNSCC患者生存数据,以HR和95%CI报告,与MiR-21的表达水平相关。我们的研究表明,MiR-21可以成功地用作HNSCC患者的预后生物标志物,证实了其致癌潜力。具体而言,这些患者中MiR-21的上调预示着生存率方面更差的结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d8a/6947266/ecc7d40dd448/jcm-08-02041-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验